The functional neuroanatomy of brain Cannabinoid receptors

Neurobiology of Disease

Volumn 5, Issue 6, 1998, Pages 417-431

  Breivogel, Christopher S ^a   Childers, Steven R ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,3 DIHYDRO 5 METHYL 3 (MORPHOLINOMETHYL) 6 (1 NAPHTHOYL)PYRROLO[1,2,3 DE][1,4]BENZOXAZINE; 4 (1,1 DIMETHYLHEPTYL) 1',2',3',4',5',6' HEXAHYDRO 2,3' DIHYDROXY 6' (3 HYDROXYPROPYL)BIPHENYL; ADENYLATE CYCLASE; CANNABINOID RECEPTOR; CORTICOTROPIN; CYCLIC AMP; CYCLIC AMP DEPENDENT PROTEIN KINASE; DRONABINOL; FOLLITROPIN; GROWTH HORMONE; GUANINE NUCLEOTIDE BINDING PROTEIN; GUANOSINE 5' O (3 THIOTRIPHOSPHATE); LUTEINIZING HORMONE;

ARTICLE; BRAIN FUNCTION; COGNITION; FEEDING; FUNCTIONAL ANATOMY; HIPPOCAMPUS; HUMAN; MEMORY; MOOD; MOTOR CONTROL; NAUSEA; NEUROENDOCRINOLOGY; NOCICEPTION; NONHUMAN; PRIORITY JOURNAL; REWARD; SENSATION; SIGNAL TRANSDUCTION; THERMOREGULATION;

EID: 0032466390     PISSN: 09699961     EISSN: None     Source Type: Journal    
DOI: 10.1006/nbdi.1998.0229     Document Type: Article

References (120)

1. Vincent B. J., McQuiston D. J., Einhorn L. H., Nagy C. M., Brames M. J. Review of cannabinoids and their antiemetic effectiveness. Drugs. 25:1983;52-62.
2. Gaoni Y., Mechoulam R. Isolation, structure, and partial synthesis of an active constituent of hashish. J. Am. Chem. Soc. 86:1964;1646-1647.
3. Hillard C. J., Harris R. A., Bloom A. S. Effects of the cannabinoids on physical properties of brain membranes and phospholipid vesicles: Fluorescence studies. J. Pharmacol. Exp. Ther. 232:1985;579-588.
4. i. Mol. Pharmacol. 29:1986;307-313.
5. Devane W. A., Dysarz F. A. I., Johnson M. R., Melvin L. S., Howlett A. C. Determination and characterization of a cannabinoid receptor in rat brain. Mol. Pharmacol. 34:1988;605-613.
6. Matsuda L. A., Lolait S. J., Brownstein M. J., Young A. L., Bonner T. I. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature. 346:1990;561-564.
7. Herkenham M., Lynn A. B., Little M. D., Johnson M. R., Melvin L. S., De Costa B. R., Rice K. C. Cannabinoid receptor localization in brain. Proc. Natl. Acad. Sci. USA. 87:1990;1932-1936.
8. Herkenham M., Lynn A. B., Johnson M. R., Melvin L. S., de Costa B. R., Rice K. C. Characterization and localization of cannabinoid receptors in rat brain: A quantitativein vitro. J. Neurosci. 11:1991;563-583.
9. Mailleux P., Vanderhaeghen J.-J. Distribution of neuronal cannabinoid receptor in the adult rat brain: A comparative receptor binding radioautography andin situ. Neuroscience. 48:1992;655-668.
10. Glass M., Dragunow M., Faull R. L. M. Cannabinoid receptors in the human brain: A detailed anatomical and quantitative autoradiographic study in the fetal, neonatal and adult human brain. Neuroscience. 77:1997;299-318.
11. Devane W. A., Hanus L., Breuer A., Pertwee R. G., Stevenson L. A., Griffin G., Gibson D., Mandelbaum A., Etinger A., Mechoulam R. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science. 258:1992;1946-1949.
12. Rinaldi-Carmona M., Barth F., Heaulme M., Shire D., Calandra B., Congy C., Martinez S., Maruani J., Neliat G., Caput D., Ferrara P., Soubrie P., Breliere J. C., Le Fur G. SR141716A, a potent and selective antagonist of the brain cannabinoid receptor. FEBS Lett. 350:1994;240-244.
13. Pertwee R. G. Pharmacology of cannabinoid CB1 and CB2 receptors. Pharmacol. Ther. 74:1997;129-180.
14. Howlett A. C. Pharmacology of cannabinoid receptors. Annu. Rev. Pharmacol. Toxicol. 35:1995;607-634.
15. Shire D., Carillon C., Kaghad M., Calandra B., Rinaldi-Carmona M., Le Fur G., Caput D., Ferrara P. An amino-terminal variant of the central cannabinoid receptor resulting from alternative splicing. J. Biol. Chem. 270:1995;3726-3731.
16. Munro S., Thomas K. L., Abu-Shaar M. Molecular characterization of a peripheral receptor for cannabinoids. Nature. 365:1993;61-65.
17. Kaminski N. E., Abood M. E., Kessler F. K., Martin B. R., Schatz A. R. Identification of a functionally relevant cannabinoid receptor on mouse spleen cells that is involved in cannabinoid-mediated immune modulation. Mol. Pharmacol. 42:1992;736-742.
18. Skaper S. D., Buriani A., Dal Toso R., Petrelli L., Romanello S., Facci L., Leon A. The ALIAmide palmitoylethanolamide and cannabinoids, but not anandamide, are protective in a delayed postglutamate paradigm of excitotoxic death in cerebellar granule cells. Proc. Natl. Acad. Sci. USA. 93:1996;3984-3989.
19. Compton D. R., Rice K. C., DeCosta B. R., Razdan R. K., Melvin L. S., Johnson M. R., Martin B. R. Cannabinoid structure-activity relationships: Correlation of receptor binding andin vivo. J. Pharmacol. Exp. Ther. 265:1993;218-226.
20. Pacheco M., Childers S. R., Arnold R., Casiano F., Ward S. J. Aminoalkylindoles: Actions on specific G-protein-linked receptors. J. Pharmacol. Exp. Ther. 257:1991;170-183.
21. Pacheco M., Ward S. J., Childers S. R. Identification of cannabinoid receptors in cultures of rat cerebellar granule cells. Brain Res. 603:1993;102-110.
22. Deadwyler S. A., Hampson R. E., Mu J., Whyte A., Childers S. R. Cannabinoids modulate voltage-sensitive potassium A-current in hippocampal neurons via a cAMP-dependent process. J. Pharmacol. Exp. Ther. 273:1995;734-743.
23. Mackie K., Hille B. Cannabinoids inhibit N-type calcium channels in neuroblastoma-glioma cells. Proc. Natl. Acad. Sci. USA. 89:1992;3825-3829.
24. Mackie K., Lai Y., Westenbroek R., Mitchell R. Cannabinoids activate an inwardly rectifying potassium conductance and inhibit Q-type calcium currents in AtT20 cells transfected with rat brain cannabinoid receptor. J. Neurosci. 15:1995;6552-6561.
25. s. J. Neurosci. 17:1997;5327-5333.
26. Maneuf Y. P., Brotchie J. M. Paradoxical action of the cannabinoid WIN 55,212-2 in stimulated and basal cyclic AMP accumulation in rat globus pallidus slices. Br. J. Pharmacol. 120:1997;1397-1398.
27. 35. Life Sci. 59:1996;659-668.
28. 35. Proc. Natl. Acad. Sci. USA. 92:1995;7242-7246.
29. 35. Mol. Pharmacol. 51:1997;87-96.
30. Dewey W. L. Cannabinoid pharmacology. Pharmacol. Rev. 38:1986;151-178.
31. Hollister L. E. Health aspects of cannabis. Pharmacol. Rev. 38:1986;1-20.
32. Pertwee R. G. The central pharmacology of psychotropic cannabinoids. Pharmacol. Ther. 36:1988;189-261.
33. Breivogel C. S., Sim L. J., Childers S. R. Regional differences in cannabinoid receptor/G-protein coupling in rat brain. J. Pharmacol. Exp. Ther. 282:1997;1632-1642.
34. Jansen E. M., Haycock D. A., Ward S. J., Seybold V. S. Distribution of cannabinoid receptors in rat brain determined with aminoalkylindoles. Brain Res. 575:1992;93-102.
35. Herkenham M., Lynn A. B., de Costa B. R., Richfield E. K. Neuronal localization of cannabinoid receptors in the basal ganglia of the rat. Brain Res. 547:1991;267-274.
36. Sim L. J., Selley D. E., Xiao R., Childers S. R. Differences in G-protein activation by mu and delta opioid, and cannabinoid, receptors in rat striatum. Eur. J. Pharmacol. 307:1996;95-107.
37. 935. J. Neurosci. 16:1996;8057-8066.
38. 9. Eur. J. Pharmacol. 323:1997;R3-R4.
39. Childers S. R., Sexton T., Roy M. B. Effects of anandamide on cannabinoid receptors in rat brain membranes. Biochem. Pharmacol. 47:1994;711-715.
40. Mackie K., Devane W. A., Hille B. Anandamide, an endogenous cannabinoid, inhibits calcium currents as a partial agonist in N18 neuroblastoma cells. Mol. Pharmacol. 44:1993;498-503.
41. Shen M., Piser T. M., Seybold V. S., Thayer S. A. Cannabinoid receptor agonists inhibit glutamatergic synaptic transmission in rat hippocampal cultures. J. Neurosci. 16:1996;4322-4334.
42. 1. Eur. J. Pharmacol. 334:1997;R1-R2.
43. Alexander G. E., Crutcher M. D. Functional architecture of basal ganglia curcuits: neural substrates of parallel processing. Trends Neurosci. 13:1990;266-271.
44. Miller A. S., Walker J. M. Effects of a cannabinoid on spontaneous and evoked neuronal activity in the substantia nigra pars reticulata. Eur. J. Pharmacol. 279:1995;179-185.
45. Tersigni T. J., Rosenberg H. C. Local pressure application of cannabinoid agonists increases spontaneous activity of rat substantia nigra pars reticulata neurons without affecting response to iontophoretically-applied GABA. Brain Res. 733:1996;184-192.
46. Sañudo-Peña M. C., Walker J. M. Role of the subthalamic nucleus in cannabinoid actions in the substantia nigra of the rat. J. Neurophysiol. 77:1997;1635-1638.
47. Pertwee R. G., Wickens A. P. Enhancement by chlordiazepoxide of catalepsy induced in rats by intravenous or intrapallidal injections of enantiomeric cannabinoids. Neuropharmacology. 30:1991;237-244.
48. Miller A. S., Walker J. M. Electrophysiological effects of a cannabinoid on neural activity in the globus pallidus. Eur. J. Pharmacol. 304:1996;29-35.
49. Maneuf Y. P., Crossman A. R., Brotchie J. M. Modulation of GABAergic transmission in globus pallidus by the synthetic cannabinoid WIN 55,212-2. Synapse. 22:1996;382-385.
50. 9. Eur. J. Pharmacol. 308:1996;161-164.
51. Heyser C. J., Hampson R. E., Deadwyler S. A. Effects of delta-9-tetrahydrocannabinol on delayed match to sample performance in rats: Alterations in short-term memory associated with changes in task specific firing of hippocampal cells. J. Pharmacol. Exp. Ther. 264:1993;294-307.
52. Terranova J.-P., Storme J.-J., Lafon N., Pério A., Rinaldi-Carmona M., Le Fur G., Soubrié P. Improvement of memory in rodents by the selective CB1 cannabinoid receptor antagonist, SR 141716. Psychopharmacology. 126:1996;165-172.
53. 9. J. Pharmacol. Exp. Ther. 239:1986;941-945.
54. 9. J. Pharmacol. Exp. Ther. 239:1986;936-940.
55. 9. J. Pharmacol. Exp. Ther. 251:1989;870-877.
56. Kirby M. T., Hampson R. E., Deadwyler S. A. Cannabinoids selectively decrease paired-pulse perforant path synaptic potentials in the dentate gyrus in vitro. Brain Res. 688:1995;114-120.
57. Norwicky A. V., Teyler T. J., Vardaris R. M. The modulation of long-term potentiation by delta-9-tetrahydrocannabinol in the rat hippocampus, in vitro. Brain Res. Bull. 19:1987;663.
58. Collins D. R., Pertwee R. G., Davies S. N. The action of synthetic cannabinoids on the induction of long-term potentiation in the rat hippocampal slice. Eur. J. Pharmacol. 259:1994;R7-R8.
59. Collins D. R., Pertwee R. G., Davies S. N. Prevention by the cannabinoid antagonist, SR141716A, of cannabinoid-mediated blockade of long-term potentiation in the rat hippocampal slice. Br. J. Pharmacol. 115:1995;869-870.
60. Stella N., Schweitzer P., Piomelli D. A second endogenous cannabinoid that modulates long-term potentiation. Nature. 388:1997;773-778.
61. Terranova J.-P., Michaud J.-C., Le Fur G., Soubrié P. Inhibition of long-term potentiation in rat hippocampal slice by anandamide and WIN 55212-2: Reversal by SR141716 A, a selective antagonist of CB1 cannabinoid receptors. Naunyn-Schmiedeberg's Arch. Pharmacol. 352:1995;576-579.
62. Bliss T. V. P., Collingridge G. L. A synaptic model of memory: Long-term potentiation in the hippocampus. Nature. 361:1993;31-39.
63. Gifford A. N., Ashby C. R. J. Electrically evoked acetylcholine release from hippocampal slices in inhibited by the cannabinoid agonist, WIN 55212-2, and is potentiated by the cannabinoid antagonist, SR 141716A. J. Pharmacol. Exp. Ther. 277:1996;1431-1436.
64. Gifford A. N., Samiian L., Gatley S. J., Ashby C. R. J. Examination of the effect of the cannabinoid agonist, CP 55,940, on electrically evoked transmitter release from rat brain slices. Eur. J. Pharmacol. 324:1997;187-192.
65. Gessa G. L., Mascia M. S., Casu M. A., Carta G. Inhibition of hippocampal acetylcholine release by cannabinoids: reversal by SR 141716A. Eur. J. Pharmacol. 327:1997;R1-R2.
66. 9. Neuropsychopharmacology. 16:1997;426-432.
67. Lichtman A. H., Martin B. R. Spinal and supraspinal components of cannabinoid-induced antinociception. J. Pharmacol. Exp. Ther. 258:1991;517-523.
68. 9. Brain Res. 578:1992;8-12.
69. Martin W. J., Lsi N. K., Patrick S. L., Tsou K., Walker J. M. Antinociceptive actions of cannabinoids following intraventricular administration in rats. Brain Res. 629:1993;300-304.
70. Lichtman A. H., Cook S. A., Martin B. R. Investigation of brain sites mediating cannabinoid-induced antinociception in rats: Evidence supporting periaqueductal gray involvement. J. Pharmacol. Exp. Ther. 276:1996;585-593.
71. Welch S. P., Thomas C., Patrick G. S. Modulation of cannabinoid-induced antinociception after intracerebroventricularversus. J. Pharmacol. Exp. Ther. 272:1995;310-321.
72. Welch S. P. Modulation of cannabinoid-induced antinociception by norbinaltorphimine, but notNN. J. Pharmacol. Exp. Ther. 265:1993;633-640.
73. 9. J. Pharmacol. Exp. Ther. 268:1994;1382-1387.
74. Hohmann A. G., Martin W. J., Tsou K., Walker J. M. Inhibition of noxious stimulus-evoked activity of spinal cord dorsal horn neurons by the cannabinoid WIN 55,212-2. Life Sci. 56:1995;2111-2118.
75. Martin W. J., Hohmann A. G., Walker J. M. Suppression of noxious stimulus-evoked activity in the ventral posterolateral nucleus of the thalamus by a cannabinoid agonist: Correlation between electrophysiological and antinociceptive effects. J. Neurosci. 16:1996;6601-6611.
76. Edsall S. A., Knapp R. J., Vanderah T. W., Roeske W. R., Consroe P., Yamamura H. I. Antisense oligodeoxynucleotide treatment to the brain cannabinoid receptor inhibits antinociception. NeuroReport. 7:1996;593-596.
77. Martin W. J., Patrick S. L., Coffin P. O., Tsou K., Walker J. M. An examination of the central sites of action of cannabinoid-induced antinociception in the rat. Life Sci. 56:1995;2103-2109.
78. Cook S. A., Welch S. P., Lichtman A. H., Martin B. R. Evaluation of cAMP involvement in cannabinoid-induced antinociception. Life Sci. 56:1995;2049-2056.
79. 9. Eur. J. Pharmacol. 12:1970;382-384.
80. 1. Eur. J. Pharmacol. 14:1971;89-92.
81. 1. Nature. 243:1973;470-471.
82. 9. Life Sci. 15:1974;329-338.
83. 9. Fertil. Steril. 26:1975;947-948.
84. 9. Pharmacol. Biochem. Behav. 20:1984;547-550.
85. 1. Neuroendocrinology. 23:1977;31-42.
86. 9. Pharmacol. Biochem. Behav. 8:1978;673-678.
87. 1. Biochem. Pharmacol. 53:1997;1919-1927.
88. Jackson A. L., Murphy L. L. Role of the hypothalamic-pituitary-adrenal axis in the suppression of luteinizing hormone release by delta-9-tetrahydrocannabinol. Neuroendocrinology. 65:1997;446-452.
89. 9. Endocrinology. 102:1977;1808-1814.
90. 9. Life Sci. 27:1980;1911-1916.
91. 9. Neuroendocrinology. 37:1983;361-370.
92. Murphy L. L., Steger R. W., Smith M. S., Bartke A. Effects of delta-9-tetrahydrocannabinol, cannabinol and cannabidiol, alone and in combinations, on luteinizing hormone and prolactin release and on hypothalamic neurotransmitters in the male rat. Neuroendocrinology. 52:1990;316-321.
93. 9. Neuroendocrinology. 43:1986;471-475.
94. Wenger T., Tóth B. E., Martin B. R. Effects of anandamide (endogenous cannabinoid) on anterior pituitary hormone secretion in adult ovariectomized rats. Life Sci. 56:1995;2057-2063.
95. Rettori V., Wenger T., Snyder G., Dalterio S., McCann S. M. Hypothalamic action of delta-9-tetrahydrocannabinol to inhibit the release of prolactin and growth hormone in the rat. Neuroendocrinology. 47:1988;498-503.
96. 9. Endocrinology. 109:1981;876-880.
97. Tyrey L. Reversal of the delta-9-tetrahydrocannabinol inhibitory effects on prolactin secretion by rostral deafferentation of the medial basal hypothalamus. Neuroendocrinology. 44:1986;204-210.
98. Murphy L. L., Rodríguez de Fonseca F., Steger R. W. Delta-9-tetrahydrocannabinol antagonism of the anterior pituitary response to estradiol in immature female rats. Steroids. 56:1991;97-102.
99. Murphy L. L., Newton S. C., Dhali J., Chávez D. Evidence for a direct anterior pituitary site of delta-9-tetrahydrocannabinol action. Pharmacol. Biochem. Behav. 40:1991;603-607.
100. Lomax P. The effects of marijuana on pituitary-thyroid activity in the rat. Agents Actions. 1:1970;252-257.
101. 9. Science. 163:1969;1464-1467.
102. Ovadia H., Wohlman A., Mechoulam R., Weidenfeld J. Characterization of the hypothermic effect of the synthetic cannabinoid HU-210 in the rat: Relation to the adrenergic system and endogenous pyrogens. Neuropharmacology. 34:1995;175-180.
103. Schmeling W. T., Hosko M. J. Hypothermic effects of intraventricular and intravenous administration of cannabinoids in intact and brainstem transected cats. Neuropharmacology. 19:1980;567-573.
104. 9. Br. J. Pharmacol. 75:1982;409-414.
105. Sallan S. E., Zinberg N. E., Frei E. Antiemetic effect of delta-9-tetrahydrocannabinol in patients receiving cancer chemotherapy. N. Engl. J. Med. 293:1975;795-797.
106. Foltin R. W., Brady J. V., Fishman M. W. Behavioral analysis of marijuana effects on food intake in humans. Pharmacol. Biochem. Behav. 25:1986;577-582.
107. Mattes R. D., Engelman K., Shaw L. M., Elsohly M. A. Cannabinoids and appetite stimulation. Pharmacol. Biochem. Behav. 49:1994;187-195.
108. London S. W., McCarthy L. E., Borison H. L. Suppression of cancer chemotherapy-induced vomiting in the cat by nabilone, a synthetic cannabinoid. Proc. Soc. Exp. Biol. Med. 160:1979;437-440.
109. Trojniar W., Wise R. A. Facilitory effects of delta-9-tetrahydrocannabinol on hypothalamically induced feeding. Psychopharmacology. 109:1991;172-178.
110. Herman T. S., Einhorn L. H., Jones S. E., Nagy C., Chester A. B., Dean J. C., Furnas B., Williams S. D., Leigh S. A., Dorr R. T., Moon T. E. Superiority of nabilone over prochlorperazine as an antiemetic in patients receiving cancer chemotherapy. N. Engl. J. Med. 300:1979;1295-1297.
111. 9. Eur. J. Pharmacol. 312:1996;273-279.
112. 3. J. Neurophysiol. 73:1995;907-910.
113. 9. Brain Res. 621:1993;65-70.
114. 1. Science. 276:1997;2048-2050.
115. Di Chiara G., Imperato A. Drugs abused by humans preferentially increase synaptic dopamine concentrations in the mesolimbic system of freely moving rats. Proc. Natl. Acad. Sci. USA. 85:1988;5274-5278.
116. 9. Neurosci. Lett. 226:1997;159-162.
117. Gifford A. N., Gardner E. L., Ashby C. R. J. The effect of intravenous administration of delta-9-tetrahydrocannabinol on the activity of A10 dopamine neurons recorded in vivo in anesthetized rats. Neuropsychobiology. 36:1997;96-99.
118. Rodríguez de Fonseca F., Carrera M. R. A., Navarro M., Koob G. F., Weiss F. Activation of corticotropin-releasing factor in the limbic system during cannabinoid withdrawal. Science. 276:1997;2050-2054.
119. Tsou K., Patrick S. L., Walker J. M. Physical withdrawal in rats tolerant to Δ9-tetrahydrocannabinol precipitated by a cannabinoid receptor antagonist. Eur. J. Pharmacol. 280:1995;R13-R15.
120. Aceto M. D., Scates S. M., Lowe J. A., Martin B. R. Cannabinoid precipitated withdrawal by the selective cannabinoid receptor antagonist, SR 141716A. Eur. J. Pharmacol. 282:1995;R1-R2.